Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|16|3|309-322

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.16, Iss.3, 2010-01, pp. : 309-322

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions

By Decker Michael W   Gopalakrishnan Murali   Meyer Michael D  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 9, 2008-09 ,pp. : 1027-1040

Informa Healthcare

Access to resources Recommend Favorite

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

By Martin Laura   Kem William   Freedman Robert  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 54-64

Springer Publishing Company

Access to resources Recommend Favorite

α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

By Geerts Hugo  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 59-65

Informa Healthcare

Access to resources Recommend Favorite

The Role of 5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia

By  

Current Pharmaceutical Design, Vol. 20, Iss. 31, 2014-09 ,pp. : 5069-5076

Bentham Science Publishers

Access to resources Recommend Favorite

Neuronal nicotinic acetylcholine receptor agonists

By Toma Lucio   Barlocco Daniela   Gelain Arianna  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 7, 2004-07 ,pp. : 1029-1040

Informa Healthcare

Access to resources Recommend Favorite